Daclizumab induction in solid organ transplantation

Bibliography

• HENRY ML, RAJAB A: The use of basiliximab in solid organ transplantation. Expert Opin. Pharmacother. (2002) 3(11):1657–1663.
   PubMedGoogle Scholar
• FERGUSON R: Acute rejection episodes-best predictor of long term primary cadaveric renal transplant survival. Clin. Transplant. (1994) 8:328–331.
   PubMed Web of Science ®Google Scholar
• QUEEN C, SCHNEIDER WP, SELICK HE et al.: A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA (1989) 86:10029–10033.
   PubMed Web of Science ®Google Scholar
• HAKIMI J, MOULD D, WALDMANN TA et al.: Development of Zenapax: a humanized anti-Tac antibody. In: Antibody Therapeutics. Harris WJ, Adair JR (Eds), CRC Press, New York, USA (1997):277–233.
   Google Scholar
• HAKIMI J, CHIZZONITE R, LUKE DR et al.: Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. Immunol (1991) 147:1352–1359.
   Web of Science ®Google Scholar
• VINCENTI F, LANTZ M, BIRNBAUM J et al.: A Phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplant recipients. Transplantation (1997) 63:33–38.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, PACE D, BIRNBAUM J,LANTZ M: Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am. J Transplant. (2003) 3:50–52.
   PubMed Web of Science ®Google Scholar
• KOCH M, NIEMEYER G, PATEL I et al: Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation (2002) 73:1640–1646.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, KIRKMAN R, LIGHT S et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl. J Med. (1998) 338:161–165.
   PubMed Web of Science ®Google Scholar
• NASHAN B, LIGHTS, HARDIE IR et al.: Reduction of acute renal allografts rejection by daclizumab. Transplantation (1999) 67:110–115.
   PubMed Web of Science ®Google Scholar
• EKBERG H, BACKMAN L, TUFVESON G et al.: Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl. Int. (2000) 13:151–159.
   PubMed Web of Science ®Google Scholar
• BUMGARDNER GL, HARDIE I, JOHNSON RWG et al.: Results of 3-year Phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation (2001) 72:839–845.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, SUZART K et al.: Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation (2002) 73:1100–1106.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, GAYNOR JJ et al.: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation (2004) 77:244–251.
   Google Scholar
• CIANCIO G, BURKE GW, GAYNOR JJet al.: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/ mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at lyear. Transplantation (2004) 77:252–258.
   Google Scholar
• ADU D, COCKWELL P, IVES NJ et al.: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials. Br. Med. J (2003) 326:1–5.
   Google Scholar
• WEBSTER AC, PLAYFORD EG, HIGGINS Get al.: Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 77:166–176.
   Google Scholar
• •A comprehensive meta-analysis evaluating the effects of IL-2Ra on outcomes such as acute rejection, graft loss and CMV infection.
   Google Scholar
• VINCENTI F, RAMOS E, BRATTSTROM C et al.: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 71:1282–1287.
   PubMed Web of Science ®Google Scholar
• AHSAN N, HOLMAN MJ, JAROWENKO MV et al.: Limited dose monoclonal IL-2 antibody induction protocol after primary kidney transplantation. Am. J. Transplant. (2002) 2:568–573.
   PubMed Web of Science ®Google Scholar
• VAN RIEMSDIJK IC, TERMEULEN RG, CHRISTIAANS MH et al.: Anti-CD25 prophylaxis allows steroid-free renal transplantation in tacrolimus-based immunosuppression. Scientific Program: American Transplant Congress. Washington DC (26 April - 1 May 2002) [Abstract 133].
   Google Scholar
• CIANCIO G, BURKE GW, SUZART K et al.: Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant. Proc. (2002) 34:1944–1945.
   PubMed Web of Science ®Google Scholar
• SARWAL MM, VIDHUN JR, ALEXANDER SR et al.: Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation (2003) 76:1331–1339.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, MATTIAZZI A, ROTH D et al.: The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin. Transplant. (2003) 17:428–432.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, SUZART K et al.: Effect of daclizumab, tacrolimus, and mycophenolate mofetil in racial minority first renal transplant recipients. Transplant. Proc. (2002) 34:1617–1618.
   PubMed Web of Science ®Google Scholar
• MEIER-KRIESCHE H-U, PALENKAR SS, FRIEDMAN GS et al.: Efficacy of daclizumab in an African-American and Hispanic renal transplant population. Transpl. Int. (2000) 13:142–145.
   PubMed Web of Science ®Google Scholar
• MEIER-KRIESCHE H-U, KAZA H, PALEKAR SS et al.: The effect of daclizumab in a high-risk renal transplant population. Clin. Transplant. (2000) 14:509–513.
   PubMed Web of Science ®Google Scholar
• EKBERG H, PERSSON NH, KALLEN R et al.: Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand. j Immunol (2003) 58:670–677.
   PubMed Web of Science ®Google Scholar
• PHILOSOPHE B, WILAND A, MANN D et al.: Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function. Scientific Program: American Transplant Congress. Washington DC (26 April - 1 May 2002) [Abstract 402].
   Google Scholar
• CHANG GJ, MAHANTY HD, VINCENTI F et al.: A calcineurin inhibitor-sparing regimen with sirolimus,
   Google Scholar
• •• mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin. Transplant. (2000) 14:550–554.
   PubMed Web of Science ®Google Scholar
• BUMGARDNER GL, RAMOS E, LIN A et al.: Daclizumab (humanized anti-IL2Ra MAB) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation (2001) 72:642–647.
   PubMed Web of Science ®Google Scholar
• BRUCE DS, SOLLINGER HW, HUMAR A et al.: Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation (2001) 72:1637–1643.
   PubMed Web of Science ®Google Scholar
• STRATTA RJ, ALLOWAY RR, HODGE E, LO A: A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin. Transplant. (2002) 16:60–68.
   PubMed Web of Science ®Google Scholar
• STRATTA RJ, ALLOWAY RR, LO A, HODGE E:Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation (2003) 8:1260–1266.
   Google Scholar
• ECKHOFF DE, MCGUIRE B, SELLERS M et al.: The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation (2000) 69:1867–1872.
   PubMed Web of Science ®Google Scholar
• FIGUERAS J, BERNARDOS A, PRIETO Met al.: Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant. Proc. (2002) 34:1511–1513.
   Google Scholar
• WASHBURN K, SPEEG KV, ESTERL R et al.: Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation (2001) 72: 1675-1679.
   Google Scholar
• NIEMEYER G, KOCH M, LIGHTS et al.: Long-term safety, tolerability and efficacy of daclizumab (Zenapax °) in a two-dose regimen in liver transplant recipients. Am. J. Transplant. (2002) 2:454–460.
   PubMed Web of Science ®Google Scholar
• •A study using two-dose daclizumab with a 4-year follow-up demonstrating a low incidence of acute rejection and infectious complications.
   Google Scholar
• HEFFRON TG, SMALLWOOD GA, PILIEN T et al.: Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant. Proc. (2002) 34:1514–1515.
   PubMed Web of Science ®Google Scholar
• HEFFRON TG, PILLEN T, SMALLWOOD GA et al.: Pediatric liver transplantation with daclizumab induction therapy. Transplantation (2003) 75:2040-2043. LIETZ K et al.: Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl. J. Med. (2000) 342:613–619.
   Google Scholar
• MANCINI D, BENIAMINOVITZ A, EDWARDS N et al.: Effect of daclizumab induction therapy on the development of cardiac transplant vasculopathy. J. Heart Lung Transplant. (2001) 20:194.
   PubMedGoogle Scholar
• CANTAROVICH M, JOYAL D, CECERE R: Early experience with low-dose daclizumab for the prevention of acute rejection in cardiac transplantation. In: Program and Abstracts of the XIX International Congress of the Transplantation Society. Miami, USA (25–30 August 2002) Abstract 2060.
   Google Scholar
• RABAGO G, MANITO N, ALMENAR L et al.: Induction therapy with two doses of daclizumab in heart transplantation: a prospective, multi centric clinical study. Interim analysis. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9–12 April 2003) Abstract 53.
   Google Scholar
• CANTAROVICH M, GIANNETTI N, CYR E et al.: Improvement of acute renal dysfunction (ARD) in heart transplant (Tx) patients (PTS) during calcineurin inhibitor (CNI) 'holiday' without rejection under anti-CD25 monoclonal antibody coverage. J. Heart Lung Transplant. (2001) 20:233.
   PubMedGoogle Scholar
• CHEN CI, MALINOWSKA K, MORAN JF et al.: Treatment of acute allograft rejection with ZENAPAX in cardiac transplant recipients. Transplantation (2001) 69:S294.
   Web of Science ®Google Scholar
• STARLING RC, MAMELOK R, BERGH CH et al.: Efficacy and safety of daclizumab with background immunosuppressive regimen in primary cardiac recipients: 12 month analysis. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9–12 April 2003) Abstract.
   Google Scholar
• GARRITY ER, VILLANUEVA J, BHORADE SM et al.: Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation (2001) 71:773–777.
   PubMed Web of Science ®Google Scholar
• BROCK MV, MORJA MC, FERBER L et al.: Induction therapy in lung transplantation: a prospective, controlled clinical trail comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant. (2001) 20:1282–1290.
   PubMed Web of Science ®Google Scholar
• BHORADE SM, VILLANUEVA J, JORDAN AM et al.: New Combination of immunosuppressive therapy decreases acute rejection in lung transplantation. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria - 12 April 2003) Abstract 143.
   Google Scholar
• CONTE JV, ALLAN SH, BORJA MC et al.: Is acute rejection primary in the development of obliterative bronchiolitis? A retrospective study of daclizumab and Thyrnoglobulin. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria -12 April 2003) Abstract 150.
   Google Scholar
• CHERIKH WS, KAUFFMAN HM, MCBRIDE MA et al.: Association of the type of induction immunosuppression with posttransplant lyrnphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation (2003) 76:1289–1293.
   PubMed Web of Science ®Google Scholar
• ••A comparison of monoclonal, polyclonal and IL-2Ra induction agents demonstrating the beneficial effects of IL-2Ra.
   Google Scholar
• Daclizumab (Zenapax) package insert. Roche. Revised July 2003. 40.BENIAMINOVITZ A, ITESCU S, BENIAMINOVITZ A, ITESCU S,
   Google Scholar